BLTE Filings — Belite Bio, Inc

BLTE Filings — Belite Bio, Inc - FilingSpy

20-F · Fiscal year ended Dec 31, 2025 · SEC filing ↗

Tinlarebant's Phase 3 DRAGON trial met its primary endpoint, and Belite Bio raised over $660M, ending 2025 with $352.9M in cash.

Tinlarebant cleared its first pivotal trial, a result that moves the company from clinical-stage to pre-registration. The net loss widened to $77.6M as operating expenses more than doubled to $84.2M, driven by a $24.6M increase in non-cash and higher trial costs, while cash and equivalents rose to $352.9M after $663.2M in financing inflows. The company now has the data and the balance sheet to pursue its first drug approval, but the cost of doing so is accelerating.

Key takeaways

The Phase 3 DRAGON trial for Stargardt disease met its primary endpoint, showing a 35.7% reduction in annualized macular lesion growth rate (p=0.0033) with a well-tolerated safety profile, and the company plans an submission to the FDA in Q2 2026.
Operating expenses more than doubled to $84.2M, with R&D rising 52% to $45.4M on higher PHOENIX trial costs and manufacturing, while SG&A rose 286% to $38.8M, overwhelmingly from a $24.6M increase in non-cash .
The net loss widened to $77.6M from $36.1M in 2024, and operating cash outflow rose to $37.0M from $29.2M, as the company remains pre-.

What changed

The DSMB recommendation to submit DRAGON data for regulatory review, flagged as the single most consequential event in 2024, was followed in 2025 by top-line results showing the trial met its primary endpoint, and the company now plans an submission in Q2 2026.
Enrollment in the PHOENIX trial for geographic atrophy, which stood at 406 of 500 subjects at the end of 2024, was completed at 530 subjects in 2025, exceeding the original target.
The cash position, flagged as a watch item at $145.2M in 2024, rose to $352.9M after the company raised $663.2M in financing, extending the runway substantially even as operating cash outflow increased to $37.0M.

What to watch

The submission to the FDA for tinlarebant in Stargardt disease, planned for Q2 2026, and any feedback or acceptance decision from the regulator.
The rate of quarterly cash burn against the $352.9M balance, as operating expenses are expected to increase with three ongoing Phase 3 trials and preparation for a potential commercial launch.
Top-line data from the Phase 3 PHOENIX trial in geographic atrophy, which will determine whether tinlarebant can address a second, larger market.

Section summaries

Quantitative and Qualitative Disclosures About Market Risk

Interest-rate and foreign-currency risks are not material; credit risk is concentrated with a single U.S. bank.

A hypothetical 10% change in market interest rates would not materially affect the fair value of the investment portfolio or results of operations.
The investment portfolio includes $139.5M in U.S. Treasury securities maturing within 3–12 months and $280.2M in 1.5-year U.S. Treasury notes.
Uninsured cash balances totaled approximately $334.6M as of December 31, 2025, and about 70% of total cash was held with one U.S. financial institution.

BLTE